BG
SLNO

Bollard Group’s Soleno Therapeutics SLNO Stock Holding History

Bollard Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,288
Closed -$106K – 325
2025
Q4 		$106K Hold
2,288
– – ﹤0.01% 204
2025
Q3 		$155K Hold
2,288
– – ﹤0.01% 168
2025
Q2 		$192K Hold
2,288
– – ﹤0.01% 182
2025
Q1 		$163K Hold
2,288
– – ﹤0.01% 169
2024
Q4 		$103K Hold
2,288
– – ﹤0.01% 183
2024
Q3 		$116K Hold
2,288
– – ﹤0.01% 194
2024
Q2 		$93K Hold
2,288
– – ﹤0.01% 201
2024
Q1 		$98K Hold
2,288
– – ﹤0.01% 195
2023
Q4 		$92K Hold
2,288
– – ﹤0.01% 193
2023
Q3 		$68K Hold
2,288
– – ﹤0.01% 204
2023
Q2 		$10K Hold
2,288
– – ﹤0.01% 305
2023
Q1 		$5K Hold
2,288
– – ﹤0.01% 269
2022
Q4 		$5K Hold
2,288
– – ﹤0.01% 262
2022
Q3 		$4K Hold
2,288
– – ﹤0.01% 269
2022
Q2 		$6K Hold
2,288
– – ﹤0.01% 273
2022
Q1 		$8K Hold
2,288
– – ﹤0.01% 408
2021
Q4 		$14K Hold
2,288
– – ﹤0.01% 406
2021
Q3 		$32K Hold
2,288
– – ﹤0.01% 373
2021
Q2 		$39K Buy
+2,288
New +$38.7K ﹤0.01% 363
2017
Q3 		– Sell
-2,563
Closed -$96K – 274
2017
Q2 		$96K Sell
2,563
-2,308
-47% -$107K 0.01% 206
2017
Q1 		$259K Sell
4,871
-231
-5% -$13.6K 0.01% 172
2016
Q4 		$310K Sell
5,102
-277
-5% -$19.2K 0.02% 166
2016
Q3 		$363K Hold
5,379
– – 0.02% 161
2016
Q2 		$468K Hold
5,379
– – 0.03% 158
2016
Q1 		$480K Hold
5,379
– – 0.04% 153
2015
Q4 		$746K Hold
5,379
– – 0.06% 142
2015
Q3 		$851K Buy
5,379
+617
+13% +$112K 0.07% 151
2015
Q2 		$1M Hold
4,762
– – 0.08% 139
2015
Q1 		$2.29M Buy
4,762
+178
+4% +$52.8K 0.17% 84
2014
Q4 		$512K Buy
+4,584
New +$945K 0.05% 150

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Bollard Group's SLNO Position: Q1 2026 in Review

Bollard Group sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 2,288 shares — an estimated $106K sold.

Bollard Group first reported a position in SLNO in Q4 2014 and held it in 30 quarters. The position peaked at $2.29M in Q1 2015. 226 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Bollard Group reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bollard Group sold 2,288 Soleno Therapeutics shares in Q1 2026, an estimated $106K.
  • Bollard Group first reported a position in Soleno Therapeutics in Q4 2014 and held it in 30 quarters.
  • Bollard Group's Soleno Therapeutics position peaked at $2.29M in Q1 2015.
  • 226 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Bollard Group's 13F filing for Q1 2026, filed 14 May 2026.